Mergers & Acquisitions

Company amends merger agreement with V.I. Technologies

Published in Clinical Trials Week, December 6th, 2004

Panacos Pharmaceuticals, Inc., a privately held company developing novel therapeutics for the treatment of HIV and other major human viral diseases, announced that it has amended the terms of its merger agreement with Watertown, Massachusetts-based V.I. Technologies, Inc., (Nasdaq: VITX), (Vitex), a biotechnology company dedicated to developing novel anti-infective technologies.

Under the terms of the amended agreement, Vitex will issue approximately 54 million shares at closing to complete the merger and acquire all Panacos outstanding shares. Panacos will have the opportunity to receive approximately 31 million additional Vitex shares, for a total of 85 million...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Clinical Trials Week

Source: Clinical Trials Week (2004-12-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry